HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Published:2019-08-06 Issue:2 Volume:178 Page:275-281
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Liu Yuanyuan,Wu Shafei,Shi Xiaohua,Luo Yufeng,Pang Junyi,Wang Changjun,Mao Feng,Liang Zhiyong,Zeng Xuan^ORCID

Funder

National Key Research and Development Program of China

Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine

National Human and Population Scientific Data Sharing Platform

Pathology Research Center of the Chinese Academy of Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05387-6.pdf

Reference14 articles.

1. Wahler J, Suh N (2015) Targeting HER2 positive breast cancer with chemopreventive agents. Curr Pharmacol Rep 1(5):324–335

2. Ross JS, Gray GS (2003) Targeted therapy for cancer: the HER-2/neu and herceptin story. Clin Leadersh Manag Rev 17(6):333–340

3. Slamon D (1990) Studies of the HER2/neu proto-oncogene in human breast cancer. Cancer Investig 8(2):253

4. Lv Q, Meng Z, Yu Y, Jiang F, Guan D, Liang C, Zhou J, Lu A, Zhang G (2016) Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer. Int J Mol Sci 17(12):E2095

5. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology; College of American Pathologists (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. https://doi.org/10.1200/jco.2013.50.9984

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer;Cancer;2024-01-13

2. Invasive Breast Cancer with HER2 ≥4.0 and;Breast Cancer: Targets and Therapy;2023-08

3. Novel markers to detect HER2 amplification in Breast cancer;2021-11-23

4. Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches;International Journal of Molecular Sciences;2021-04-29

5. VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer;Frontiers in Oncology;2021-01-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3